Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...

Attruby maker BridgeBio is re-upping its “Don’t Pass on Your Heart Health” campaign with a fresh new beat.  | BridgeBio's YouTube awareness push to lead up to World Amyloidosis Day features a ...

The FDA has warned Evolus over an Instagram reel that made the “especially problematic” suggestion of blurred lines between a ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through.

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...